News Releases

News Releases

Mar 01, 2022
-- UGN-301 is an investigational immunotherapy designed for monotherapy and combination therapy in treating low-grade and high-grade disease -- PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 1, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing
Feb 03, 2022
-- ENVISION Study Design Similar to Successful UGN-102 Phase 2b OPTIMA II Trial -- PRINCETON, N.J. --(BUSINESS WIRE)--Feb. 3, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers,
Jan 05, 2022
PRINCETON, N.J. --(BUSINESS WIRE)--Jan. 5, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced that it will present at the following virtual healthcare